Targeting mitochondria in triple-negative breast cancer: Emerging therapeutic and drug development strategies

Area of Science:

• Mitochondrial biology and cancer therapeutics

Background:

• Mitochondria regulate critical cellular processes like metabolism and apoptosis.
• Mitochondrial dysfunction is increasingly recognized as a key driver in triple-negative breast cancer (TNBC).

Purpose of the Study:

• To systematically review the roles of mitochondrial dysfunction in TNBC.
• To summarize current and emerging mitochondria-targeted therapeutic strategies for TNBC.

Main Methods:

• Comprehensive literature review of mitochondrial dysfunction in TNBC.
• Analysis of therapeutic strategies targeting mitochondria in TNBC, including direct and indirect approaches.
• Examination of novel delivery systems and compounds.

Main Results:

• Mitochondrial dysfunction contributes to TNBC initiation, progression, metabolic reprogramming, immune evasion, and cell death.
• Current therapies include direct mitochondrial protein targeting, pathway modulation, and combination regimens.
• Emerging strategies involve nanoparticles and compounds with mitochondrial regulatory effects.

Conclusions:

• Targeting mitochondria offers a promising avenue for developing precise and effective TNBC therapies.
• Further research into mitochondria-targeted approaches is crucial for advancing TNBC treatment.